{"id":634146,"date":"2023-01-16T16:30:02","date_gmt":"2023-01-16T16:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634146"},"modified":"2023-01-16T16:30:02","modified_gmt":"2023-01-16T16:30:02","slug":"cutaneous-tcell-lymphoma-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-tcell-lymphoma-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634146.html","title":{"rendered":"Cutaneous T-Cell Lymphoma Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1673848198.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cutaneous T-Cell Lymphoma Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1673848198.jpeg\" alt=\"Cutaneous T-Cell Lymphoma Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Cutaneous T-Cell Lymphoma Clinical Trials<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cCutaneous T-Cell Lymphoma (CTCL) &#8211; Pipeline Insight, 2023,\u201d report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Cutaneous T-Cell Lymphoma (CTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Cutaneous T-Cell Lymphoma Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Cutaneous T-Cell Lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cutaneous T-Cell Lymphoma pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Cutaneous T-Cell Lymphoma Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 25+ Cutaneous T-Cell Lymphoma pipeline therapies are in various stages of development, and their anticipated acceptance in the Cutaneous T-Cell Lymphoma market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Cutaneous T-Cell Lymphoma companies developing novel drug candidates to improve the Cutaneous T-Cell Lymphoma treatment landscape include<strong> Soligenix, Moleculin Biotech, Innate Pharma, Bioniz, Codiak BioSciences, <\/strong>and others.<\/li>\n<li>Promising Cutaneous T-Cell Lymphoma pipeline therapies in various stages of development include <strong>SGX301, WP1220, Lacutamab, BNZ-1, exoIL 12<\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cutaneous T-Cell Lymphoma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help your body&#8217;s germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin.<\/p>\n<p style=\"text-align: justify;\">Cutaneous T-cell lymphoma can cause rash-like skin redness, slightly raised or scaly round patches on the skin, and, sometimes, skin tumors.<\/p>\n<p style=\"text-align: justify;\">Several types of cutaneous T-cell lymphoma exist. The most common type is mycosis fungoides. Sezary syndrome is a less common type that causes skin redness over the entire body. Some types of cutaneous T-cell lymphoma, such as mycosis fungoides, progress slowly and others are more aggressive.<\/p>\n<p style=\"text-align: justify;\">The type of cutaneous T-cell lymphoma you have helps determine which treatments are best for you. Treatments can include skin creams, light therapy, radiation therapy and systemic medications, such as chemotherapy.<\/p>\n<p style=\"text-align: justify;\">Cutaneous T-cell lymphoma is one of several types of lymphoma collectively called non-Hodgkin&#8217;s lymphoma.<\/p>\n<p style=\"text-align: justify;\"><strong>Cutaneous T-Cell Lymphoma Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>SGX301: Soligenix<\/strong><\/p>\n<p style=\"text-align: justify;\">SGX301 is a novel first-in-class photodynamic therapy utilizing safe, visible light for activation.&nbsp; The active ingredient in SGX301 is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions, is taken up by the malignant T-cells, and then activated by fluorescent light 16 to 24 hours later.&nbsp; Currently, it is in the Phase III stage of clinical trial evaluation to treat Cutaneous T-Cell Lymphoma<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Cutaneous T-Cell Lymphoma drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Cutaneous T-Cell Lymphoma Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Cutaneous T-Cell Lymphoma Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Soligenix<\/li>\n<li>Moleculin Biotech<\/li>\n<li>Innate Pharma<\/li>\n<li>Bioniz<\/li>\n<li>Codiak BioSciences<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cutaneous T-Cell Lymphoma Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>SGX301<\/li>\n<li>WP1220<\/li>\n<li>Lacutamab<\/li>\n<li>BNZ-1<\/li>\n<li>exoIL 12<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cutaneous T-Cell Lymphoma Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>By development stage<\/li>\n<li>By product type<\/li>\n<li>By route of administration<\/li>\n<li>By molecule type<\/li>\n<li>By MOA type&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Cutaneous T-Cell Lymphoma Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Cutaneous T-Cell Lymphoma Companies<\/strong>: Soligenix, Moleculin Biotech, Innate Pharma, Bioniz, Codiak BioSciences, and others<\/li>\n<li><strong>Key Cutaneous T-Cell Lymphoma Pipeline Therapies<\/strong>: SGX301, WP1220, Lacutamab, BNZ-1, exoIL 12, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Cutaneous T-Cell Lymphoma treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Cutaneous T-Cell Lymphoma Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report to know more about the different phases of drug development @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Cutaneous T-Cell Lymphoma Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cutaneous-tcell-lymphoma-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cutaneous-tcell-lymphoma-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cutaneous T-Cell Lymphoma Clinical Trials DelveInsight\u2019s, \u201cCutaneous T-Cell Lymphoma (CTCL) &#8211; Pipeline Insight, 2023,\u201d report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Cutaneous T-Cell Lymphoma (CTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-tcell-lymphoma-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634146.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,403],"tags":[],"class_list":["post-634146","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634146"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634146\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}